Is Thymosin Alpha-1 Legal in Georgia?

What Is Thymosin Alpha-1 and Why Does Its Legal Status Matter?

Thymosin Alpha-1 (also written TA-1 or Tα1) is a 28-amino-acid peptide derived from the larger precursor protein prothymosin alpha, first isolated by Allan Goldstein, Ph.D., at George Washington University in the 1970s. The immune-modulating properties of this peptide attracted early clinical research in chronic hepatitis B and C, certain cancers, and primary immunodeficiency states. The commercial form, thymalfasin (brand name Zadaxin, manufactured by SciClone Pharmaceuticals), is approved in approximately 35 countries, but the U.S. Food and Drug Administration has never granted it approval as a finished drug product.

That gap between international approval and U.S. Non-approval is the single most important legal fact for any Georgia patient or prescriber to understand. Without an FDA-approved new drug application (NDA) or biologics license application (BLA), Thymosin Alpha-1 cannot be legally marketed as a drug in the United States through conventional channels. The question that follows is whether compounding law creates a lawful alternative pathway, and in Georgia, the answer is a conditional yes.

Why International Approval Does Not Equal U.S. Legality

Approval in another country carries no weight with the FDA. Each jurisdiction has its own review process. Zadaxin's approvals in China, Italy, and elsewhere were granted under those countries' regulatory frameworks and do not transfer to the U.S. Market. A Georgia prescriber citing foreign approvals as justification for prescribing Thymosin Alpha-1 outside of compliant compounding pathways would still be operating outside U.S. Law.

The Clinical Rationale Behind Growing Patient Interest

Interest in Thymosin Alpha-1 has grown substantially among patients seeking immune support, particularly after COVID-19. A 2020 study published in the Journal of Infectious Diseases (PMID 32785655) found that thymalfasin reduced 28-day mortality in severe COVID-19 patients with lymphopenia, adding momentum to off-label demand. [1] Separately, a 2019 systematic review in PLOS ONE (PMID 31504033) summarized evidence across 39 clinical trials for hepatitis B treatment, noting generally favorable immune response data. [2] That evidence base is precisely why physicians want to prescribe it and why regulators are still studying its risk-benefit profile.

Federal Legal Framework: The FDA's Position on Thymosin Alpha-1

Understanding Georgia law requires understanding federal law first, because federal rules set the ceiling for what any state can permit.

The FDA Bulks List and Category 2 Status

The FDA regulates compounded preparations through Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which governs traditional compounding pharmacies, and Section 503B, which governs outsourcing facilities producing larger batches. Both sections allow pharmacies to compound drugs from bulk active pharmaceutical ingredients (APIs), but only if those APIs appear on the FDA's approved bulk drug substances list or are not otherwise restricted. [3]

Thymosin Alpha-1 was previously nominated for the FDA's Category 2 bulks list for 503A compounding, but per FDA's current bulks-list page, that nomination was withdrawn and the substance is no longer categorized as Category 2. [4] Withdrawal is not FDA approval: Thymosin Alpha-1 is not on the 503A bulks list, and compounding it is not covered by any interim-policy enforcement discretion, so FDA's original safety concerns remain on record. Practically speaking, this creates ongoing legal exposure. Compounders operating under 503A who compound Thymosin Alpha-1 do so entirely outside the bulks-list safe harbor and face potential enforcement risk regardless of its withdrawn status.

For 503B outsourcing facilities, the standard is stricter. The FDA has indicated that outsourcing facilities should not compound substances that are on the Category 2 list without a clinical need justification supported by adequate evidence. This distinction matters to Georgia patients because some national telehealth pharmacies operate under 503B licenses.

What "Not FDA-Approved" Actually Means for Patients

The absence of an NDA means no FDA-reviewed label exists specifying indications, contraindications, or standardized dosing. Compounded Thymosin Alpha-1 is therefore prepared according to a prescriber's clinical judgment and current published literature, not a manufacturer's approved package insert. The American College of Clinical Pharmacy has noted that off-label compounding demands heightened prescriber documentation to establish medical necessity. [5]

Research Chemical Designation

Some online vendors sell Thymosin Alpha-1 labeled "for research purposes only, not for human use." This designation does not make the product legal for personal therapeutic use. Purchasing peptides from these vendors and self-injecting them constitutes use of an unapproved drug under the FD&C Act, regardless of the vendor's labeling. The FDA has issued multiple warning letters to research-chemical vendors selling peptides for implied human use; enforcement actions are on record at FDA.gov. [6]

Georgia State Legal Framework

Georgia does not have a state statute that specifically bans or specifically approves Thymosin Alpha-1. The relevant Georgia-specific legal framework comes from three sources: the Georgia State Board of Pharmacy, the Georgia Composite Medical Board, and the Georgia Medical Practice Act (O.C.G.A. Title 43, Chapter 34).

Georgia State Board of Pharmacy Rules

The Georgia State Board of Pharmacy, operating under O.C.G.A. § 26-4-1 et seq., requires all compounding pharmacies operating in or shipping to Georgia to comply with USP standards (primarily USP Chapters 795 and 797) and with all applicable federal law, including the FD&C Act and the Drug Quality and Security Act (DQSA) of 2013. [7] A Georgia-licensed pharmacy that compounds Thymosin Alpha-1 must:

• Obtain the API from an FDA-registered supplier
• Compound only in response to a valid patient-specific prescription
• Comply with USP 797 sterile compounding standards, because Thymosin Alpha-1 is an injectable
• Maintain records demonstrating the clinical rationale

Out-of-state pharmacies shipping compounded Thymosin Alpha-1 into Georgia must hold a valid Georgia non-resident pharmacy permit in addition to their home-state licenses.

The Medical Practice Act and Prescriber Obligations

Under O.C.G.A. § 43-34-8, Georgia physicians practicing medicine must maintain an acceptable standard of care. Prescribing a compounded peptide that has no FDA-approved indication requires that the physician document:

1. A legitimate patient-physician relationship (in-person or via a compliant telemedicine visit under O.C.G.A. § 33-24-56.4)
2. A clinical indication supported by published evidence or recognized clinical practice
3. Informed consent that the substance lacks FDA approval and carries unknown long-term risks

The Georgia Composite Medical Board has not issued a specific guidance document on peptide therapy as of the date of this article. Physicians are therefore governed by the general standard-of-care framework and by federal compounding law.

Telemedicine Prescribing in Georgia

Georgia's telemedicine law, substantially updated in 2020, allows physicians to establish a valid patient-physician relationship via synchronous audio-video visits. [8] This means a Georgia resident can legally receive a Thymosin Alpha-1 prescription from a Georgia-licensed or multi-state-licensed physician through a telehealth platform, provided the visit meets the standard-of-care documentation requirements described above. The prescription can then be sent to a compliant 503A compounding pharmacy.

How to Legally Obtain Thymosin Alpha-1 in Georgia

The only legally compliant pathway for a Georgia resident to obtain Thymosin Alpha-1 for personal therapeutic use is through a valid prescription from a licensed physician, filled by an FDA-compliant 503A compounding pharmacy.

Step 1: Establish Care With a Licensed Prescriber

The prescriber must be licensed in Georgia or hold a valid multi-state license covering Georgia. The visit, whether in-person or via telemedicine, must include a medical history review, an assessment of the clinical indication, and documentation of informed consent. Physicians who specialize in integrative medicine, immunology, infectious disease, or functional medicine are most likely to have familiarity with the published evidence base for Thymosin Alpha-1.

Step 2: Receive a Patient-Specific Prescription

The prescription must identify the patient by name, specify the dose (commonly 1.6 mg per injection), the frequency (typically one to two times per week, based on protocols used in the hepatitis B trials [2]), the route of administration (subcutaneous injection), and the quantity. Generic prescriptions or standing orders without patient-specific information do not satisfy 503A requirements.

Step 3: Use an FDA-Registered 503A Compounding Pharmacy

The pharmacy must:

• Be registered with the FDA under the DQSA
• Source Thymosin Alpha-1 API from an FDA-registered bulk manufacturer
• Operate under USP 797 sterile compounding standards
• Hold a current Georgia pharmacy license or non-resident pharmacy permit

Patients should ask their pharmacy directly whether their Thymosin Alpha-1 API supplier is FDA-registered and whether the facility has passed recent state board inspections.

What to Avoid

• Purchasing from research-chemical websites. This violates federal law regardless of how the product is labeled.
• Using overseas pharmacies. Importation of unapproved drugs through personal import channels is generally prohibited under 21 U.S.C. § 381, with only narrow FDA personal importation discretion policies applying, and those policies do not cover injectable peptides.
• Sharing prescriptions. A compounded prescription is patient-specific. Sharing it is a federal offense.

Clinical Evidence Summary: What the Research Actually Shows

The legal question is inseparable from the clinical rationale, because prescriber documentation of medical necessity depends on the quality of available evidence.

Hepatitis B and Hepatitis C

A meta-analysis published in the World Journal of Gastroenterology (PMID 26078567) analyzed 16 randomized controlled trials involving thymalfasin in chronic hepatitis B and reported significantly higher rates of HBeAg seroconversion compared to interferon monotherapy, with a pooled odds ratio of 2.18 (95% CI 1.51 to 3.14, P<0.001). [9] For hepatitis C, evidence is less consistent, and the advent of direct-acting antivirals has largely displaced thymalfasin from that indication.

Immune Reconstitution in Cancer

A 2018 randomized trial in the Journal of Clinical Oncology (PMID 29406800) evaluated Thymosin Alpha-1 in patients undergoing chemotherapy for non-small-cell lung cancer (N=120) and found that the thymalfasin arm had a statistically significant reduction in grade 3 to 4 infections (18% vs. 34%, P<0.05) and a shorter median hospital stay. [10] These data are frequently cited by integrative oncology prescribers.

COVID-19 and Sepsis

The 2020 Journal of Infectious Diseases study noted above (PMID 32785655) enrolled 76 patients with severe COVID-19 and lymphopenia. [1] The thymalfasin group showed a 28-day mortality rate of 11% compared with 30% in the control group. The trial was small and observational, and larger replication studies have not yet been completed, so these findings should be interpreted with caution.

Safety Profile

Across clinical trials, Thymosin Alpha-1 has shown a favorable tolerability profile. The most commonly reported adverse events are mild injection-site reactions occurring in roughly 5% to 10% of patients. No serious hepatotoxicity, nephrotoxicity, or immunosuppression has been reported in published trial data. The absence of an FDA-reviewed label means long-term safety data under conditions of compounded manufacture are not systematically tracked.

Gray Areas and Enforcement Risks

The Category 2 Limbo Problem

The nomination that once placed Thymosin Alpha-1 under Category 2 review was withdrawn, and FDA's current bulks-list page no longer lists it as under active review. That withdrawal is not approval: Thymosin Alpha-1 remains off the 503A bulks list, and compounding it is not shielded by any interim-policy enforcement discretion, so FDA's originally stated safety concerns stay on record. Prescribers and patients should treat this as an unresolved legal position rather than a cleared one when making treatment decisions.

Advertising Claims

Georgia physicians and telehealth platforms cannot legally advertise Thymosin Alpha-1 as a cure, treatment, or prevention for any specific disease in the absence of FDA approval. Making such claims would expose the practice to FTC scrutiny and potential Georgia Composite Medical Board disciplinary action.

Interstate Commerce Considerations

A compounding pharmacy in another state shipping Thymosin Alpha-1 to a Georgia patient is engaged in interstate commerce and must comply with both federal law and Georgia's non-resident pharmacy permit requirements. Patients who order from out-of-state pharmacies without verifying Georgia permit status may unknowingly receive product from a non-compliant supplier.

HealthRX.com Clinical Perspective

HealthRX.com physicians reviewing this topic apply the following framework when evaluating a Thymosin Alpha-1 prescription request from a Georgia patient:

1. Clinical indication check. Is there a published, peer-reviewed evidence base (at least one RCT or systematic review) supporting use for the patient's specific condition?
2. Compounding pharmacy vetting. Has the pharmacy provided documentation of its FDA registration, API supplier's FDA registration, and most recent USP 797 inspection result?
3. Informed consent documentation. Does the patient's chart include a signed informed consent form acknowledging Category 2 status, absence of FDA approval, and the possibility that compounding access could be restricted?
4. Monitoring plan. Is there a defined follow-up schedule (typically at 4 weeks and 12 weeks) to assess response and document adverse events?

Only when all four criteria are met do HealthRX.com-affiliated physicians proceed with prescribing.

Comparing Georgia to Other States

Georgia's approach to peptide compounding is broadly consistent with the majority of U.S. States, which rely on federal 503A/503B law rather than state-specific peptide statutes. A small number of states have enacted stricter pharmacy board policies that effectively limit peptide compounding; Georgia is not among them as of the date of this review. However, states do periodically update pharmacy board guidance, and Georgia prescribers should monitor the Georgia State Board of Pharmacy's bulletin page for any new policies affecting compounded injectables.

FDA's bulks-list page shows Category 2 status can shift quickly, as it did in April 2026 when a group of peptide nominations was withdrawn. [4] Georgia prescribers should check FDA.gov directly rather than assume a fixed timeline, since Thymosin Alpha-1's nomination is now withdrawn, it is not on the 503A bulks list, and it carries no interim-policy enforcement discretion.